AI-based drug developer Basecamp valued at $800 million after $140 million funding round
The oversubscribed round will fund next-generation EDEN models and AI-designed therapies for cancer and autoimmune diseases, the company said.
- On Wednesday, September 23, 2026, London-based Basecamp Research announced it raised $140 million in a Series C funding round, valuing the AI-based drug developer at $800 million.
- The oversubscribed financing, led by S32, will fund the development of the company's EDEN models, which are trained on its proprietary Trillion Gene Atlas dataset collected across more than 30 countries.
- Investors including NVIDIA, Anthropic, and the Rockefeller Foundation joined the round, while S32 General Partner Andy Conrad, former CEO of Google's Verily, joins the Basecamp board of directors.
- Basecamp aims to develop in vivo cell therapies for cancer and autoimmune diseases, seeking to lower costs compared to current treatments that the company said cost "hundreds of thousands of dollars per patient."
- While the company has demonstrated strong preclinical results, Basecamp co-founder and CEO Glen Gowers said the funding brings this technology closer to patients, though no clinical trial timeline was provided.
26 Articles
26 Articles
Basecamp raises $140M before the clinic; J&J and Compass’ potential rivalry
Some of the biggest news and trends captured in PharmaVoice’s newsletter this week. Sign up here to receive the newsletter daily. Another big AI haul Investors are still lining up to back AI drug developers before their candidates reach human trials. Basecamp Research...
AI-based drug developer Basecamp valued at $800 million after $140 ...
PR Newswire
Basecamp Research raises $140M to advance AI-designed therapeutics
/PRNewswire/ -- Basecamp Research, a frontier AI company developing AI-designed medicines, today announced a $140M Series C financing to train a new generation...
Basecamp Research raises £100m+ to ‘cure incurable diseases’
Basecamp Research has raised $140 million (£106m) in Series C financing to continue developing its AI-designed medicines. Basecamp’s ambition is to develop cures for diseases that remain incurable by designing medicines that reprogram the body to repair itself. The company combines frontier AI models trained on proprietary biological data with technology for writing DNA sequences into cells. “We believe the future of medicine lies in reprogramm…
Verdict Hospital
Pharmaceutical Business reviewBasecamp Research secures $140m for AI-driven therapies
Basecamp Research has secured $140m in a Series C funding round to train a new generation of its EDEN biological foundation models and advance AI-designed therapies towards clinical development.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
